Publication

Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents: Interim Report


Released:

Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures.

In the National Defense Authorization Act for Fiscal Year 2002, Congress directed the Secretary of Defense to contract with the Institute of Medicine and the National Research Council (NRC) for a study of the review and approval process for new medical countermeasures in order to identify new approaches to accelerate that process and to identify methods for assuring that new countermeasures will be safe and effective.

The Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare agents has released this interim report that provides information on study progress, but does not contain findings and recommendations.